New drug could treat patients hospitalised with COVID-19 pneumonia: Lancet study
The Hindu
The trial carried out between June 2020 and February 2021 involved patients aged over 16 with COVID-19 pneumonia either being treated on a ward or ICU at nine hospitals across the U.K.
A newly identified drug may be used to effectively treat some patients hospitalised with COVID-19 pneumonia, according to a study published in The Lancet Respiratory Medicine journal The team, including researchers from the University of Birmingham and the University of Oxford, U.K., tested namilumab— an antibody already in late-stage trials to treat rheumatoid arthritis —in patients hospitalised with COVID-19 pneumonia.
The patients were receiving 'usual' care, as well as having high levels in their blood of a marker of inflammation known as C reactive protein (CRP).
CRP levels rise when there is inflammation in the body, and elevated levels of CRP have been found to be a potential early marker to predict risk for severity of COVID-19, the researchers said.